Table 1 Baseline clinicopathological characteristics categorized by overall population, EGFR, and PD-L1 (SP263) status

Sex

 Male

160 (36%)

63 (44%)

56 (30%)

0.007

63 (31%)

24 (45%)

0.043

 Female

281 (64%)

80 (56%)

133 (70%)

143 (69%)

29 (55%)

Age, years

  < 65

137 (31%)

41 (29%)

62 (32%)

0.559

61 (30%)

19 (36%)

0.381

  ≥ 65

304 (69%)

99 (71%)

130 (68%)

145 (70%)

34 (64%)

COPD

36 (8%)

20 (14%)

8 (4%)

0.001

11 (5%)

8 (15%)

0.033

Smoking

 Never

212 (48%)

56 (40%)

104 (54%)

 < 0.001

108 (52%)

23 (43%)

0.085

 Former/Current

123 (28%)

54 (39%)

36 (19%)

47 (23%)

20 (38%)

ECOG

 0–1

339 (77%)

117 (84%)

146 (76%)

0.095

162 (79%)

42 (79%)

0.924

 Unknown

102 (23%)

23 (16%)

46 (24%)

44 (21%)

11 (21%)

CEA

  < 3.8 ng/ml

141 (32%)

47 (34%)

61 (32%)

0.881

71 (16%)

13 (25%)

0.127

  ≥ 3.8 ng/ml

80 (18%)

24 (17%)

31 (16%)

29 (7%)

13 (25%)

Surgery procedure

 Lobectomy

377 (85%)

117 (84%)

164 (85%)

0.645

173 (84%)

48 (91%)

0.227

 Wedge resection or segmentectomy

64 (15%)

23 (16%)

28 (15%)

33 (16%)

5 (9%)

Pathology

 Adenocarcinoma

415 (94%)

128 (92%)

187 (97%)

0.017

196 (95%)

51 (96%)

1

 Adenosquamous

23 (5%)

9 (6%)

5 (3%)

9 (4%)

2 (4%)

 NSCLC, NOS

3 (1%)

3 (2%)

0

1 (1%)

0

HIstology subtype

 MIA

13 (3%)

3 (2%)

2 (1%)

 < 0.001

3 (1%)

1 (2%)

 < 0.001

 Lepidic

106 (24%)

26 (19%)

47 (24%)

56 (27%)

5 (9%)

 Acinar

192 (44%)

42 (30%)

104 (54%)

92 (45%)

21 (40%)

 Papillary

38 (9%)

10 (7%)

21 (11%)

20 (10%)

7 (13%)

 Micropapillary

15 (3%)

9 (6%)

5 (3%)

5 (2%)

2 (4%)

 Solid

26 (6%)

15 (11%)

6 (3%)

4 (2%)

9 (17%)

 Mucinous

33 (7%)

24 (17%)

4 (2%)

20 (10%)

3 (6%)

pT

 T1

246 (56%)

71 (51%)

106 (55%)

0.012

117 (57%)

27 (51%)

0.861

 T2a

99 (22%)

24 (17%)

52 (27%)

45 (22%)

14 (26%)

 T2b

31 (7%)

12 (8%)

14 (7%)

14 (7%)

4 (8%)

 T3

52 (12%)

25 (18%)

16 (24%)

25 (12%)

6 (11%)

 T4

13 (3%)

8 (6%)

4 (2%)

5 (2%)

2 (4%)

pN

 N0

365 (82%)

115 (82%)

150 (78%)

0.756

175 (85%)

34 (64%)

0.003

 N1

38 (9%)

11 (8%)

20 (10%)

13 (6%)

6 (11%)

 N2

38 (9%)

14 (10%)

22 (11%)

18 (9%)

13 (25%)

Margin

 Negative

429 (97%)

135 (96%)

185 (96%)

0.971

199 (97%)

51 (96%)

1

 Positive

12 (3%)

5 (4%)

7 (4%)

7 (3%)

2 (4%)

LVI

 Negative

284 (64%)

84 (60%)

120 (63%)

0.871

141 (68%)

25 (47%)

0.006

 Positive

142 (32%)

52 (37%)

66 (34%)

58 (23%)

26 (49%)

Pleural invasion

 Negative

292 (66%)

88 (63%)

125 (65%)

0.335

132 (64%)

32 (60%)

0.031

 Positive

113 (26%)

41 (29%)

45 (23%)

47 (23%)

16 (30%)

Pathological staging

 I

301 (68%)

80 (57%)

132 (69%)

0.061

145 (70%)

26 (49%)

0.003

 II

82 (19%)

37 (27%)

32 (17%)

36 (18%)

11 (21%)

 III

58 (13%)

23 (16%)

28 (14%)

25 (12%)

16 (30%)

Adjuvant systemic treatment

 Cisplatin-based

45 (10%)

16 (11%)

26 (14%)

0.194

19 (9%)

11 (21%)

0.122

 Carboplatin-based

44 (10%)

17 (12%)

15 (8%)

17 (8%)

6 (11%)

 Others

5 (1%)

2 (1%)

3 (2%)

3 (1%)

1 (2%)

 Unknown

3 (1%)

3 (2%)

0

2 (1%)

0

Adjuvant radiation

 RT alone

2 (0.5%)

2 (1%)

0

0.292

0

2 (4%)

0.005

 CCRT

6 (1%)

1 (0.7%)

4 (2%)

4 (2%)

1 (2%)

 Sequential

17 (14%)

8 (6%)

8 (4%)

7 (3%)

6 (11%)

Recurrent

 Locoregional

20 (5%)

10 (7%)

9 (5%)

0.585

41 (20%)

16 (30%)

0.229

 Distant metastasis

99 (22%)

39 (28%)

51 (27%)

9 (4%)

3 (6%)

CNS metastasis

19 (4%)

6 (4%)

11 (6%)

0.556

5 (2%)

4 (8%)

0.088